Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation
A Randomized, Placebo-Controlled Double-Blind Trial Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation: A Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Recipient of a kidney transplant at UNMC, including cadaveric or living donor transplant.
Exclusion Criteria:
- A previous diagnosis of diabetes or previous criteria for diabetes, according to the American Diabetes Association, not previously recognized as diabetes.
- Simultaneous transplant of another solid organ, such liver or heart.
- Patient unable to take oral medication.
- Patient unable to give informed consent.
- Hypersensitivity to sitagliptin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: placebo
|
Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min.
The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min.
The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
|
|
Experimental: Sitagliptin 100 mg daily
sitagliptin 100 mg daily
|
Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min.
The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min.
The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fasting Blood Glucose
Time Frame: 1 year
|
Fasting blood glucose levels at 1 year
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HbA1c
Time Frame: 1 year
|
HbA1c at 1 year
|
1 year
|
|
eGFR
Time Frame: 1 year
|
estimated glomerular filtration rate (eGFR) at 1 year
|
1 year
|
|
Hypoglycemia
Time Frame: 1 year
|
Number of episodes of hypoglycemia (blood glucose less than 70 mg/dl)
|
1 year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUC for Glucose
Time Frame: 1 year
|
Area Under the Curve for glucose after OGTT
|
1 year
|
|
AUC for Insulin
Time Frame: 1 year
|
Area Under the Curve for insulin after OGTT
|
1 year
|
|
AUC for Proinsulin
Time Frame: 1 year
|
Area Under the Curve for Proinsulin after OGTT
|
1 year
|
|
AUC for C Peptide
Time Frame: 1 year
|
Area Under the Curve for C peptide after OGTT
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Vijay Shivaswamy, MD, University of Nebraska
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Kidney Diseases
- Urologic Diseases
- Endocrine System Diseases
- Disease Attributes
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Diabetes Mellitus
- Kidney Failure, Chronic
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Dipeptidyl-Peptidase IV Inhibitors
- Sitagliptin Phosphate
Other Study ID Numbers
Other Study ID Numbers
- 0254-09-FB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.